OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
November 09, 2023
Fruquintinib (Fruzaqla) is the first novel chemotherapy-free treatment option approved for metastatic colorectal cancer in more than a decade.
November 08, 2023
Tirzepatide (Zepbound; Eli Lilly and Company) is expected to be available in the United States by the end of 2023 with a list price of $1,059.87.
Company aims to receive approval on a Type II Variation application for Sirturo for patients with pulmonary tuberculosis.
The online promotion of intravenous infusions and oral forms of subanesthetic ketamine for the treatment of mental health conditions has been found to frequently carry misleading or false information.
November 07, 2023
Exagamglogene autotemcel (Exa-Cel) was assigned a Prescription Drug User Fee Act action date of December 8, 2023, for the treatment of sickle cell disease.
October 27, 2023
Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.
October 25, 2023
Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.
October 16, 2023
Multiple regulatory pathways exist during the drug development process.
October 10, 2023
Klein discusses how recent FDA draft guidelines will impact the use of SaMD in the life sciences industry.
September 29, 2023
The proposed rule is aimed at ensuring the safety and effectiveness of the tests.